Tagrisso 40 Mg. Tagrisso 80 Mg 40 mg. 80 mg FC tablet)
PDF Leaflet Revision Date: 07 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Adjuvant treatment and first-line therapy for EGFR mutation-positive NSCLC.
Dosage (summary)
80 mg once daily; may reduce to 40 mg based on tolerance.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly (>65 years)
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; use effective contraception.
Key Drug Interactions
- Strong CYP3A4 inducers
- CYP3A4 inhibitors
- BCRP and P-gp substrates
Contraindications
- Hypersensitivity
- St. John's Wort
- Pregnancy and Lactation
Common side effects
- Diarrhoea
- Rash
- Paronychia
- Dry skin
- Stomatitis
Counselling Points
- Take with or without food
- Monitor for respiratory symptoms
- Report signs of SJS
Serious warnings
- Interstitial lung disease
- QTc interval prolongation
- Stevens-Johnson syndrome
Important Disclaimer
The Tagrisso 40 Mg. Tagrisso 80 Mg 40 mg. 80 mg FC tablet) professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
